Pfizer, MMV Partner To Develop Treatment For IPTp
A product development team comprised of representatives from Pfizer, MMV and the London School of Hygiene and Tropical Medicine (LSHTM) are expected to coordinate the trials and an external independent Data Monitoring Committee of malaria experts will oversee them.
Under the terms of the agreement, Pfizer plans to seek marketing authorization in selected malaria-endemic African countries where, with MMV, it is expected to seek to introduce the use of this important potential therapy to improve pregnancy outcomes and neonatal survival.
Additionally, MMV is expected to provide several levels of support and advocacy on behalf of the project, including the development of a patient education campaign and recommendations on registration strategies in malaria-endemic countries.
Pfizer, the LSHTM and MMV have been informally working on the project for almost two years. The formal partnership will commence after signing with Phase III clinical trials expected to begin in Africa this summer with up to 5,000 participants.
Jean-Michel Halfon, president and general manager of emerging markets business unit at Pfizer, said: “Pfizer believes that an affordable price for public sector sales of the medicine, in endemic countries, if approved, is an important step towards increasing access and safe intermittent preventive treatment for pregnant women.”
Dennis Schmatz, president and CEO of MMV, said: “We are proud to be working with the Pfizer team by supporting the clinical trials of AZCQ for intermittent preventive treatment in this highly vulnerable patient group, and look forward to advancing this exciting combination toward registration.”
Will the partnership further treatment process for IPTp?
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.